Open call for submissions! The Canadian Nephrology Trials Network is planning our next virtual research symposium. Our network includes nephrologists, researchers and patient partners. This event is free and open to all. A great opportunity to present your work!
Please contact Alicia Murdoch amurdoch@cansolveckd.ca
Watch our Spring Virtual Research Symposium below
In collaboration with the University of South Australia, Drs. Bohm, MacRae, Thompson and Zimmerman and patient partner Nancy Verdin are conducting an international survey exploring exercise and physical activity practices and perceptions among peritoneal dialysis (PD) clinicians. The results will directly inform the development of exercise guidelines for people receiving PD.
The survey has been approved by the University of South Australia research ethics board, as it’s being conducted in collaboration with the Global Renal Exercise Network.
The survey has 13 questions and takes approximately 8 minutes to complete. Survey link HERE
A poster showcasing CNTN was available for view and to download at the recent Can-SOLVE CKD Network Annual Meeting September 9 and 10. The poster highlighted a timeline from inception to now, as well as highlighting our network goals, vision and what we offer. PDF version available here: CNTN Infographic PDF
Recording of the Annual Meeting available
Congratulations to CNTN members Patient Partner Mary Beaucage, Dr. Amber Molnar, Dr. Sam Silver and Dr. Michael Zappitelli who were part of a team that was awarded a CIHR Spring 2021 Project Grant
Project Title: Filling Knowledge Gaps for the Success of Ontario Renal Plan 3
Principal investigator(s):Weir, Matthew A; Beaucage, Mary; Blake, Peter G; Chanchlani, Rahul; Clark, Edward G; Clemens, Kristin K; Dixon, Stephanie N; Harel, Ziv; Jain, Arsh K; Molnar, Amber; Silver, Samuel; Sood, Manish M; Zappitelli, Michael
Read how Can-SOLVE CKD Network brought together their patient partners and CNTN members to envision a bright future for CNTN in the Canadian Journal of Kidney Health and Disease
Alicia Murdoch, Karthik K. Tennankore, Clara Bohm, Catherine M. Clase, Adeera Levin, Hans Vorster and Rita S. Suri
First Published July 14, 2021
In October 2020, Kidney International published the International Consensus Definitions of Clinical Trial Outcomes for Kidney Failure: 2020 developed from the 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials hosted by the ISN in Vancouver, Canada.
The event included Can-SOLVE CKD and CNTN patient partners.
The paper has been summarized into a slide deck and user guide for developing clinical trial protocols. Click on the link to download the PDF and Powerpoint slides.
The Capacity Building Committee and Communications and Engagement Committee are looking for additional members. These committees meet monthly for 1 hour to discuss ideas and move forward initiatives.
The Capacity Building Committee is focused on training and development of CNTN membership and the mentorship of new investigators and patient partners. Their mandate is to increase the number of people and resources available to conduct clinical trials in Canada and to increase the number of research ideas or questions developed by both patients and physicians.
The Communications and Engagement Committee’s mission is to increase the exposure of CNTN to the nephrology community across Canada thereby increasing membership to facilitate more collaboration with academic and non-academic sites across Canada and keeping that community informed about what is happening in the research community.
Email the CNTN project manager, Alicia at amurdoch@cansolveckd.ca, if you have questions or would like to join the committee.
, and
From the editorial: “Those who manage and fund Canada’s health care systems need to view high-priority trials as an integral part of clinical care and to provide adequate and stable infrastructure funding, thus avoiding the current time-consuming and expensive process of developing separate data-sharing agreements and contracts with many hospitals and organizations. ”
Patient engagement is a relatively new way of conducting research in Canada and many researchers are probably still wondering how to do it well. Dr. Simon Hatcher and his team at the Ottawa Hospital developed a graphic novel style tip sheet, “Top 10 Recommendations for Researchers Working with Lived Experience Partners“.
The comic was created by people with lived experience of suicide at the REFLECT research forum which brought together patients and caregivers as well as suicide prevention researchers, trainees and policy-makers.
Dr. Bhanu Prasad and his research team are conducting a feasibility study of a randomized controlled trial investigating renal denervation as a possible treatment option in patients with Loin Pain Hematuria Syndrome (LPHS). Dr. Prasad presented this study at the CNTN meeting in November 2019 in Washington, D.C and we look forward to hearing more about the study at future CNTN meetings.
Loin Pain Hematuria Syndrome (LPHS) is a poorly understood clinical condition characterized by severe pain localized to the kidney but in the absence of identifiable urinary tract disease. Case reports/series have shown renal denervation via catheter-based radiofrequency ablation to be an effective therapeutic option for the treatment of LPHS. To determine whether catheter-based renal denervation is a meaningful addition to the treatment options in these often difficult to treat LPHS patients, a randomized clinical trial is needed. Prior to conducting a definitive trial that focuses on patient outcomes, ensuring the feasibility of undertaking such a trial is required. As such, we will conduct a single-centre randomized control feasibility trial designed to determine viability and provide framework and direction for a larger trial.
The research team will conduct a double-blinded, parallel-group, partial crossover, sham-controlled, randomized feasibility trial on 10 LPHS patients at the Regina General Hospital, Saskatchewan. Participants will be randomized into either renal denervation (treatment group) or a sham treatment (control group). Data (pain, quality of life, mood, disability) will be collected from both groups at baseline, 6 weeks, 3 and 6 months after the intervention. After the initial 6-month follow-up is over, the participants who received the sham procedure will cross over into the treatment group and will be followed for an additional 6 months in the same manner as the treatment group.
The lessons learnt from this trial will lay the framework and direction for conducting a multi-site randomized controlled trial involving a larger cohort of patients.
